27.01.2011 • NewsRanbaxy LaboratoriesRanbaxyDaiichi Sankyo

Ranbaxy CEO Omesh Sethi Quits

Ranbaxy Laboratories, India's top drugmaker, said on Thursday its chief financial officer had resigned, the third top official to quit after Japan's Daiichi Sankyo took majority control.

The company, with annual sales of about $1.7 billion, did not give a reason for Omesh Sethi's resignation but said it was effective Jan. 25.

Shares in Ranbaxy, which the market values at about $5 billion, fell as much as 1.7 percent to 554.15 rupees in a subdued Mumbai market.

Sethi's exit comes less than six months after then chief executive Atul Sobti left citing a rift in strategy.

Daiichi had bought the holdings of Chairman and CEO Malvinder Singh and his family in 2008 and later made an open offer, in a deal valued at $5.4 billion, giving the Japanese No.3 drugmaker a launch pad to expand its generic offerings.Singh stepped down from the company in 2009.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read